Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Net Income From Continuing Operations : ¥954 Mil (TTM As of Mar. 2024)

View and export this data going back to 2001. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Tianjin Pharmaceutical Da Ren Tang Group's net income from continuing operations for the three months ended in Mar. 2024 was ¥383 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2024 was ¥954 Mil.

Tianjin Pharmaceutical Da Ren Tang Group Net Income From Continuing Operations Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group Net Income From Continuing Operations Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

635.36

679.66

786.88

873.26

968.71

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Net Income From Continuing Operations	Get a 7-Day Free Trial															397.78	316.69	127.56	126.68	383.38

Tianjin Pharmaceutical Da Ren Tang Group Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥954 Mil.

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SHSE:600329) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

T14:Singapore

Address

No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193

Website

http://www.jydrt.com.cn

Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Tianjin Pharmaceutical Da Ren Tang Group (SHSE:600329) Headlines

No Headlines